Imbio PHA (4.0.0) vs iCAC Device
AI Verdict
Choose Imbio PHA (4.0.0) if…
Choose Imbio PHA (4.0.0) if your primary need is to rapidly assess right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism or hypertension. This tool is specifically designed for analysis of CT pulmonary angiogram (CTPA) scans, providing automated measurements of cardiac structures to inform clinical decisions in acute or suspected cardiopulmonary conditions.
View Imbio PHA (4.0.0) →Choose iCAC Device if…
Choose iCAC Device if you aim to opportunistically detect and quantify coronary artery calcium (CAC) from routine, non-contrast, non-gated chest CT scans. This is ideal for identifying patients at risk for cardiovascular disease from existing imaging data, even when the original scan was performed for non-cardiac indications, thereby aiding in early cardiovascular disease detection and risk stratification.
View iCAC Device →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Imbio PHA (4.0.0) | iCAC Device |
|---|---|---|
| Pricing | Unknown | Contact for pricing |
| Deployment | Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel). | Software as a Medical Device (SaMD), integrates with PACS or DICOM router. Cloud-based (via Carebricks platform). |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Imbio PHA (4.0.0)Imbio PHA emphasizes seamless integration with native DICOM tools and workflows, delivering annotated images and summary reports directly into the PACS without additional steps for the physician. Its rapid, fully-automated assessment, typically in minutes, further enhances its ease of use for radiologists.
Clinical Value
Imbio PHA (4.0.0)Imbio PHA aids in the diagnosis and risk stratification of pulmonary embolism and hypertension by providing automated measurements of cardiac structures from CTPA scans, which are crucial for immediate patient management and long-term risk assessment. Clinical performance validation has shown its accuracy in measuring RV/LV ratios compared to expert radiologists, helping standardize reporting of right heart strain.
Pricing & Value
TieBoth Imbio PHA and iCAC Device explicitly state 'contact for pricing'. Without specific cost details or transparent pricing models for either tool, it is impossible to conduct a head-to-head comparison of their financial value.
Enterprise Readiness
Imbio PHA (4.0.0)Imbio PHA offers flexible deployment options, including cloud, enterprise (on-premise), or via partners, catering to diverse institutional IT infrastructures. Furthermore, it explicitly states HIPAA compliance with third-party certification by Compliancy Group and implied BAA availability, providing clear assurances for enterprise adoption.
Innovation
iCAC DeviceBunkerhill Health's iCAC Device demonstrates significant innovation by opportunistically detecting and quantifying coronary artery calcium from routine, non-contrast, non-gated chest CT scans that were not originally ordered for cardiac assessment. This approach leverages existing imaging data to identify early cardiovascular disease risk without additional patient burden, representing a novel application of AI in population health.
Support & Docs
Imbio PHA (4.0.0)Imbio PHA provides clear and detailed information regarding its support channels, including phone and email contacts, an online case submission form, and explicit mention of readily available user manuals and product documentation. Specific support and documentation details for iCAC Device were not readily available in the provided information or web search results.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Imbio PHA (4.0.0) | iCAC Device |
|---|---|---|
| Product Name | Imbio PHA (4.0.0) | iCAC Device |
| Primary Function | Measures cardiac structures from CTPA scans to assess potential right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension. | Detects and quantifies coronary artery calcium from routine, non-contrast, non-gated chest CT scans, aiding in early cardiovascular disease detection. |
| Input Scan Type | CT pulmonary angiogram (CTPA) scans | routine, non-contrast, non-gated chest CT scans |
| Key Measurements/Outputs | Automated measurement of right and left ventricle diameters; automated measurement of main pulmonary artery and aorta diameters; calculates RV/LV and PA/Ao ratios; generates annotated DICOM images; provides summary reports in PDF format. | Estimates presence and quantity of coronary artery calcium (CAC); outputs visual representation of estimated CAC segmentation; delivers exact and four-category quantitative estimates of CAC burden in Agatston units. |
| AI Algorithm Type | artificial intelligence algorithms (for anatomical identification and measurement) | deep-learning algorithms |
| Integration | Integrates with native DICOM tools and workflows. | Integrates with PACS or DICOM router; integrates with EHRs via the Carebricks platform. |
Videos
Demos, reviews, and walkthroughs featuring Imbio PHA (4.0.0) and iCAC Device.